{
  "docId": "019de077-8566-7247-8a65-bb40d287c138",
  "docSlug": "3a5ef691e659aba2296672e3bbfa035c",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2025-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 36,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "timeline",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a dual-track timeline approach to show the progression from observational data collection to clinical trial phases.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-8566-7247-8a65-bb40d287c138/21",
  "deckHref": "/decks/019de077-8566-7247-8a65-bb40d287c138",
  "deckJsonHref": "/decks/019de077-8566-7247-8a65-bb40d287c138.json",
  "deckAnchorHref": "/decks/019de077-8566-7247-8a65-bb40d287c138#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.22,
        "y": 0.955
      },
      "kind": "disclaimer",
      "text": "*Subject to continued U.S. government funding and timelines",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b138dd70-2b39-4cdb-ac00-cb10d48465a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.92,
        "x": 0.036,
        "y": 0.55
      },
      "kind": "framework",
      "text": "Timeline of clinical milestones from 2024 to 2027",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca51da2f-9f2b-4af9-bc16-0bd32d1e039c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.33,
        "x": 0.64,
        "y": 0.317
      },
      "kind": "list",
      "text": "Primary endpoint is to evaluate mortality (epetaborole + ceftazidime/meropenem vs. placebo + ceftazidime/meropenem)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8af5d01-8e2f-4fb3-8486-f5caf1d7b90b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.43,
        "x": 0.088,
        "y": 0.317
      },
      "kind": "list",
      "text": "200 patients enrolled at 3 sites in 12 months (Thailand and Laos); Confirmed high mortality (~27% 28-day; ~50% 90-day all-cause)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa551c91-bc03-41fe-aacb-dabf19ecc6ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.23,
        "x": 0.036,
        "y": 0.215
      },
      "kind": "title",
      "text": "Planned timeline",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "148dc61a-2dee-4abe-ab1d-ff1e792ebf21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.025,
        "y": 0.04
      },
      "kind": "title",
      "text": "Goal to Significantly Reduce Mortality in Melioidosis Treated Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "239ba20b-961a-47e6-bc92-c08074afcf3e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "fa520487-fa39-4c65-af6b-bd5d8481ac19",
      "evidence": "Visual representation of project phases over a calendar timeline.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 21,
      "from": 18,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ca1bff99-ab8b-4217-9926-524e39a8b895",
      "evidence": "The document presents the potential benefits of AN2 Therapeutics' pipeline candidates in reducing mortality and improving patient outcomes.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing these diseases?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}